VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: D. Chapman who wrote (1078)	7/31/1999 11:59:00 AM
From: David Bogdanoff	Read Replies (1) of 1972

DC; Regarding your patently unobjective and dismissive comments regarding Vical's technology, please be aware that a 20% (or less) response rate is common for many highly regarded drug therapies and is more than enough for FDA approval and commercial success. This is especially true for life threatening and generally incurable diseases such as cancer. I note that CORR is achieving commercial success with a heart treatment that improves the odds of patient survival by approximatley 1% over previous therapies. Anyone knowledgeable about the efficacy of drugs today would not deride a potential 20% response rate for cancer. In your case, you are either not knowledgeable or hoping that the readers of this thread are not. You needn't bother replying to posting this as I am not interested in at best ill-informed views on Vical. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next